Clinical trials: Mediastinal Large B-cell Lymphoma
Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
This is a Phase 1b/2, open-label, non-randomized multicenter study to assess the safety and efficacy of ibrutinib and lenalidomide in combination with DA-EPOCH-R in subjects with relapsed/refractory Diffuse Large B-cell Lymphoma…
- Trial name
- NCT02142049
- Testing
- Ibrutinib, DA-EPOCH-R, Lenalidomide
- Where
- 10 sites in United States
- Volunteers
- 35 people
- Sponsor
- Pharmacyclics LLC.
Diffuse Low Grade B-Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Italian Observational Study on CAR-T Therapy for Lymphoma
The goal of this observational study on chimeric antigen receptor T-cell therapy is to monitor the feasibility, efficacy, toxicity and biomarkers in a real life setting.
- Conditions
- Diffuse Low Grade B-Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Mantle Cell Lymphoma, Follicular Lymphoma
- Trial name
- CART-SIE (NCT06339255)
- Where
- Italy
- Volunteers
- 5,300 people
- Sponsor
- Paolo Corradini
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma
JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This phase Ib trial studies whether anti-CD19-chimeric antigen receptor (CAR) lentiviral vector-transduced autologous T cells (JCAR014) and durvalumab are safe in combination and can work together in treating patients with…
- Conditions
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Trial name
- NCT02706405
- Testing
- Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Cyclophosphamide, Durvalumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma, Large Cell, Diffuse, Lymphoma, Mixed Cell, Diffuse
CT-011 MAb in DLBCL Patients Following ASCT
Autologous peripheral blood stem cell transplantation combined with high dose chemotherapy is the treatment of choice given to patients with diffuse large-B cell lymphoma (DLBCL) following relapse of the disease.
- Conditions
- Lymphoma, Large Cell, Diffuse, Lymphoma, Mixed Cell, Diffuse, Primary Mediastinal Large B-Cell Lymphoma
- Trial name
- NCT00532259
- Testing
- CT-011
- Where
- 27 sites in United States, India and 1 more
- Volunteers
- 72 people
- Sponsor
- CureTech Ltd
Primary Mediastinal Large B Cell Lymphoma
A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment
The purpose of this multi-center, single arm, phase Ⅱ clinical trail is to evaluate the efficacy and toxicity of sintilimab combined with R-CHOP regimen as first-line treatment for primary mediastinal large B-cell Lymphoma (PMBCL)
- Trial name
- NCT06412068
- Testing
- Combined anti-PD-1 and R-CHOP
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Non-Hodgkin Lymphoma, T-Cell Lymphoma
Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
The SCORE-NHL study is a prospective, multi-center, study designed to collect data and biological samples from participants diagnosed with aggressive Stage I to IV non-Hodgkin Lymphoma (NHL).
- Conditions
- Non-Hodgkin Lymphoma, T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, High-Grade B-Cell Lymphoma
- Trial name
- SCORE-NHL (NCT07750886)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Natera, Inc.
Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma
This phase II trial is studying how well sunitinib works in treating patients with relapsed or refractory diffuse or mediastinal large B-cell lymphoma.
- Conditions
- Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT00392496
- Testing
- sunitinib malate
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Burkitt's Lymphoma, Burkitt's Leukemia
Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults
The study evaluates the efficacy and tolerability of alternating short cycles of high-dose and conventional chemotherapy in combination with rituximab in CD20 positive patients, followed by local radiation therapy in the case of…
- Conditions
- Burkitt's Lymphoma, Burkitt's Leukemia, Mediastinal Neoplasms, Lymphoblastic Lymphoma
- Trial name
- NCT00199082
- Testing
- Adriamycin, Cyclophosphamide, Cytarabine
- Where
- Germany
- Volunteers
- 650 people
- Sponsor
- Nicola Goekbuget
Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study
The present study consists of a retrospective multicentric collection of all consecutive patients with PMBCL diagnosed over the time period considered (13 years, from 2007 to 2019 inclusive).
- Trial name
- NCT05162170
- Where
- 40 sites in Italy
- Volunteers
- 633 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Lymphoma
Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00689845
- Testing
- bleomycin sulfate, filgrastim, rituximab
- Where
- 8 sites in United Kingdom
- Volunteers
- 120 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
This is a Phase 1, open-label, two-part, safety, PK, and activity study designed to characterize the DDI potential of tazemetostat. Tazemetostat will be taken orally BID continuously in 28-day cycles in both study parts.
- Conditions
- Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma, Mantle Cell Lymphoma, Advanced Solid Tumor
- Trial name
- NCT03028103
- Testing
- Tazemetostat, Fluconazole, Omeprazole
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Epizyme, Inc.
Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL)
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T…
- Conditions
- Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma
- Trial name
- NCT04186520
- Testing
- 8/12-Day Production of Car-T Cells, 8/12-Day Production of Cryopreserved Car-T Cells, 12-Day Production of Car-T Cells
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Medical College of Wisconsin
Primary Mediastinal B-cell Lymphoma
Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma
Primary mediastinal large B cell lymphoma is treated with a combination of chemotherapy and the monoclonal antibody rituximab (chemoimmunotherapy).
- Trial name
- NCT01599559
- Testing
- observation, 3D-Conformal Radiotherapy (3D-CRT)
- Where
- 85 sites in United States, Argentina and 12 more
- Volunteers
- 540 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma
Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This phase II trial studies how well brentuximab vedotin, bendamustine, and rituximab work in treating patients with B-cell non-Hodgkin lymphoma that has returned after a period of improvement or has not responded to previous…
- Conditions
- Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma, Grey Zone Lymphoma, High Grade B Cell Lymphoma
- Trial name
- S-BR (NCT02623920)
- Testing
- Brentuximab, Bendamustine, Rituximab
- Where
- United States
- Sponsor
- University of Arizona
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma
This is an open-label, multicenter, dose-escalation phase 1 study to determine the safety and efficacy of BZ019 in relapsed or refractory CD19+ B-cell Lymphoma.
- Conditions
- Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma, Primary Mediastinal Large B Cell Lymphoma
- Trial name
- NCT04067414
- Testing
- BZ019
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy
This study evaluates whether tumors present in patients with cancer who are planned to get CAR T-cells have low amounts of oxygen (hypoxia).
- Conditions
- Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Malignant Neoplasm
- Trial name
- NCT04409314
- Testing
- Fluorine F 18-fluoroazomycin Arabinoside, Positron Emission Tomography
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of California, San Francisco
Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma
PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy
This phase II trial studies the effect of brentuximab vedotin and nivolumab alone and in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone in treating patients with untreated, stage I-IV primary…
- Conditions
- Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Trial name
- PACIFIC (NCT04745949)
- Testing
- Brentuximab Vedotin, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory
A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
The primary purpose of the study is to assess the pharmacokinetics (PK) profile of pembrolizumab following subcutaneous (SC) injection of pembrolizumab coformulated with hyaluronidase, and to evaluate the objective response rate…
- Conditions
- Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent, Primary Mediastinal Large B-cell Lymphoma Refractory
- Trial name
- NCT06504394
- Testing
- Pembrolizumab (+) Berahyaluronidase alfa
- Where
- 29 sites in United States, Australia and 9 more
- Volunteers
- 66 people
- Sponsor
- Merck Sharp & Dohme LLC
Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
This phase I/II trial finds out the best dose, possible benefits and/or side effects of ALX148 in combination with rituximab and lenalidomide in treating patients with indolent and aggressive B-cell non-Hodgkin lymphoma.
- Conditions
- Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma
- Trial name
- NCT05025800
- Testing
- CD47 Antagonist ALX148, Lenalidomide, Rituximab
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL)
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
This study is designed as a long-term follow-up study of participants who have receive genetically modified autologous CLBR001 CAR-T cells
- Conditions
- Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT04488354
- Testing
- CLBR001 and SWI019
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Calibr, a division of Scripps Research